Movement Alert｜Akeso Rises 3.07% in Regular Trading, Technical Rebound After Four-Day Selloff as Multiple Brokerages Maintain Buy Ratings

Market Focus09:32

On June 5, Akeso rose 3.07% in regular trading, trading at 101.2 HKD/share, with trading volume of 49.5 million HKD. The stock rebounded after four consecutive sessions of decline following the ASCO conference catalyst, during which it had accumulated losses exceeding 14% and briefly breached the 100 HKD level.

On the news front, multiple institutions recently issued research reports reaffirming bullish outlooks. CICC maintained its Outperform rating with a target price of 184 HKD; BOCOM International maintained Buy with a 175 HKD target; Nomura upgraded the stock to Buy; CITIC Construction Investment maintained Buy, projecting revenues of 4.82 billion, 7.61 billion, and 10.61 billion yuan for 2026-2028; and Guosen Securities maintained its Outperform rating. Bank of America also raised its target price to 164 HKD, reiterating Buy. The broad institutional consensus points to Akeso's core product ivonescimab redefining the first-line treatment standard for squamous NSCLC following the landmark HARMONi-6 OS data presented at the ASCO Plenary Session.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127662643?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127662643","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 3.07% in Regular Trading, Technical Rebound After Four-Day Selloff as Multiple Brokerages Maintain Buy Ratings","media":"Market Focus","content":"<p><p>On June 5, Akeso rose 3.07% in regular trading, trading at 101.2 HKD/share, with trading volume of 49.5 million HKD. The stock rebounded after four consecutive sessions of decline following the ASCO conference catalyst, during which it had accumulated losses exceeding 14% and briefly breached the 100 HKD level.</p><p>On the news front, multiple institutions recently issued research reports reaffirming bullish outlooks. CICC maintained its Outperform rating with a target price of 184 HKD; BOCOM International maintained Buy with a 175 HKD target; Nomura upgraded the stock to Buy; CITIC Construction Investment maintained Buy, projecting revenues of 4.82 billion, 7.61 billion, and 10.61 billion yuan for 2026-2028; and Guosen Securities maintained its Outperform rating. Bank of America also raised its target price to 164 HKD, reiterating Buy. The broad institutional consensus points to Akeso's core product ivonescimab redefining the first-line treatment standard for squamous NSCLC following the landmark HARMONi-6 OS data presented at the ASCO Plenary Session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 3.07% in Regular Trading, Technical Rebound After Four-Day Selloff as Multiple Brokerages Maintain Buy Ratings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 3.07% in Regular Trading, Technical Rebound After Four-Day Selloff as Multiple Brokerages Maintain Buy Ratings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, Akeso rose 3.07% in regular trading, trading at 101.2 HKD/share, with trading volume of 49.5 million HKD. The stock rebounded after four consecutive sessions of decline following the ASCO conference catalyst, during which it had accumulated losses exceeding 14% and briefly breached the 100 HKD level.</p><p>On the news front, multiple institutions recently issued research reports reaffirming bullish outlooks. CICC maintained its Outperform rating with a target price of 184 HKD; BOCOM International maintained Buy with a 175 HKD target; Nomura upgraded the stock to Buy; CITIC Construction Investment maintained Buy, projecting revenues of 4.82 billion, 7.61 billion, and 10.61 billion yuan for 2026-2028; and Guosen Securities maintained its Outperform rating. Bank of America also raised its target price to 164 HKD, reiterating Buy. The broad institutional consensus points to Akeso's core product ivonescimab redefining the first-line treatment standard for squamous NSCLC following the landmark HARMONi-6 OS data presented at the ASCO Plenary Session.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1127662643","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127662643","pubTimestamp":1780623149,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, Akeso rose 3.07% in regular trading, trading at 101.2 HKD/share, with trading volume of 49.5 million HKD. The stock rebounded after four consecutive sessions of decline following the ASCO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易涨3.07%，四日抛售后技术性反弹，多家券商维持买入评级","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 5, Akeso rose 3.07% in regular trading, trading at 101.2 HKD/share, with trading volume of 49.5 million HKD. The stock rebounded after four consecutive sessions of decline following the ASCO conference catalyst, during which it had accumulated losses exceeding 14% and briefly breached the 100 HKD level.On the news front, multiple institutions recently issued research reports reaffirming bullish outlooks. CICC maintained its Outperform rating with a target price of 184 HKD; BOCOM International maintained Buy with a 175 HKD target; Nomura upgraded the stock to Buy; CITIC Construction Investment maintained Buy, projecting revenues of 4.82 billion, 7.61 billion, and 10.61 billion yuan for 2026-2028; and Guosen Securities maintained its Outperform rating. Bank of America also raised its target price to 164 HKD, reiterating Buy. The broad institutional consensus points to Akeso's core product ivonescimab redefining the first-line treatment standard for squamous NSCLC following the landmark HARMONi-6 OS data presented at the ASCO Plenary Session.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127662643","isCrawlerRequest":true}